Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a sterile intrauterine solution for intrauterine use. It provides targeted analgesia during uterine procedures, helping to reduce pain for women undergoing interventions such as hysteroscopy, intrauterine device placement, or uterine curettage.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑ready documentation for global distribution. It offers reliable cold‑chain logistics where required to maintain product integrity.

Lidbree, containing lidocaine, is employed for analgesia in intrauterine procedures and related gynecologic interventions.

- Hysteroscopic procedures: provides local anesthesia of the uterine cavity to reduce procedural pain. - Intrauterine device (IUD) insertion: minimizes discomfort during placement of contraceptive devices. - Uterine curettage: facilitates analgesia during scraping of the uterine lining.

Lidbree may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Local burning sensation at the application site - Mild uterine cramping - Nausea - Dizziness or headache

Serious or Rare Side Effects: - Allergic reactions including rash, angioedema, or anaphylaxis - Methemoglobinemia leading to cyanosis - Cardiac arrhythmias such as ventricular tachycardia - Central nervous system toxicity presenting as seizures or loss of consciousness

When using Lidbree, clinicians should observe several precautionary measures to ensure patient safety. - Assess allergy: verify patient has no known hypersensitivity to lidocaine or amide‑type local anesthetics. - Monitor cardiac status: observe for signs of arrhythmia or hypotension during and after administration. - Use lowest effective dose: limit exposure to the minimum amount required for analgesia. - Avoid in severe hepatic impairment: reduced metabolism may increase systemic toxicity. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lidbree can interact with other medicines, influencing its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase systemic lidocaine toxicity. - Beta‑blockers (e.g., propranolol): can potentiate cardiotoxic effects of lidocaine. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Class III antiarrhythmics (e.g., amiodarone, sotalol): may modestly elevate lidocaine levels. - Concurrent use of other local anesthetics: cumulative toxicity risk. - Epinephrine administered nearby: can alter lidocaine absorption and prolong action.